Viatris Inc. or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?

SG&A Cost Management: Viatris vs. HUTCHMED

__timestampHUTCHMED (China) LimitedViatris Inc.
Wednesday, January 1, 2014266840001499100000
Thursday, January 1, 2015298290001923500000
Friday, January 1, 2016395780002351400000
Sunday, January 1, 2017432770002564000000
Monday, January 1, 2018486450002397300000
Tuesday, January 1, 2019529340002503400000
Wednesday, January 1, 2020613490003344600000
Friday, January 1, 20211271250004529200000
Saturday, January 1, 20221361060004179100000
Sunday, January 1, 20231331759994650100000
Loading chart...

Unleashing the power of data

Managing SG&A Costs: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Viatris Inc. and HUTCHMED (China) Limited, two prominent players, showcase contrasting strategies over the past decade. From 2014 to 2023, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023. In contrast, HUTCHMED's expenses grew more modestly, reaching around $133 million in the same year. This disparity highlights Viatris's expansive operations compared to HUTCHMED's more streamlined approach. Notably, Viatris's SG&A expenses surged by over 200% from 2014 to 2023, while HUTCHMED's increased by nearly 400%, albeit from a much smaller base. These trends underscore the diverse strategies in managing operational costs, reflecting each company's unique market positioning and growth ambitions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025